Skip to content

Press Release · Press Releases

Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026

Issued by PR Newswire

Image: PR Newswire

Updated longer-term analysis, including up to four years of follow-up data in patients with relapsed or refractory BRAF-altered pediatric low-grade glioma treated with OJEMDA®(tovorafenib), will be presented as an oral presentation on November 14 at 3:45 p.m. EST Data expand on clinically...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

/C O R R E C T I O N - WeaveGrid/

In the news release, North Carolina's Electric Cooperatives Launches EVConnectNC, Powered by WeaveGrid, to Maximize Charging During Lower Demand and Power Cost Periods, issued 20-Oct-2026 by WeaveGrid over PR Newswire, we are advised by the company that changes have been made. The...

PR Newswire ·